Skip to main content
. 2022 Jul 4;6(7):e736. doi: 10.1097/HS9.0000000000000736

Figure 1.

Figure 1.

Budget impact model structure of r/r DLBCL patients treated with CAR T-cells over a 6-y time horizon from the perspective of the German statutory health insurance. 2L = Second-line; 3L = Third-line; cumulative costs = aggregated costs over the 6-y time horizon; CAR = chimeric antigen receptor; r/r DLBCL = relapsed or refractory diffuse large B-cell lymphoma.